Psilocybin, the prodrug found in over 200 species of psychedelic mushrooms, was first identified and synthesized in 1957. Clinical observations from the 1950s and 1960s suggested potential therapeutic effects for depressive symptoms, anxiety, and conversion disorder, despite scientific design limitations. After being classified as a Schedule I substance in 1970, renewed scientific interest since the 1990s has produced further evidence supporting its therapeutic use for psychiatric disorders including pathological anxiety, mood depressive disorder, and addiction.
Psychedelics from plants have been used for millennia in religious and spiritual practices. In 1957, Dr. Hofmann identified and synthesized psilocybin, a prodrug found in over 200 species of psychedelic mushrooms. Despite limitations in study design, clinical observations from the 1950s and 1960s suggested psilocybin had potential therapeutic effects for depressive symptoms, anxiety, and conversion disorder. Classified as a Schedule I substance in 1970, scientific interest revived in the 1990s. Recent studies provide further evidence supporting the hypothesis that psilocybin may be useful for treating psychiatric disorders such as pathological anxiety, mood depressive disorder, and addiction.